Table 2.

Cases of anaphylaxis (n = 6) associated with administration of repeated courses of rasburicase (n = 97)

Diagnosis	Total number of courses	Total rasburicase exposure [mg]	Comorbid conditions prior to rasburicase administration	Time between first course and anaphylaxis [days]	Time between rasburicase administration and anaphylaxis [minutes]	Intensive care unit admission	Intubation and cardiac arrest	Death
Multiple myeloma	2	6	End-stage renal disease, pancytopenia, fever, hypertension, mucositis, kyphoscoliosis	22	112	Yes	Yes	No
Chronic myeloproliferative disorder	2	6	Asthma, chronic kidney disease, deep vein thrombosis, chronic pain, insomnia	21	337	Yes	Yes	Yes
Multiple myeloma	2	9	Pneumonia, acute kidney injury, urinary tract infection	695	40	No	No	No
Multiple myeloma	3	12	Acute kidney injury, hypotension, pneumonia, urinary tract infection	319	10	No	No	No
Multiple myeloma	2	6	Decompensated congestive heart failure, peripheral neuropathy, chronic kidney disease	150	<10	No	No	No
Multiple myeloma	4	18	Hypertension, pancytopenia, acute kidney injury, type 2 diabetes mellitus, anxiety, depression	335	59	Yes	No	No